^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Prostate Cancer
    Drug:abiraterone acetate (CYP17A1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Natl Compr Canc Netw
    Title:

    Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study

    Published date:
    05/14/2021
    Excerpt:
    AR amplification and TP53 and/or RB1 alterations were associated with resistance to abiraterone or docetaxel.
    DOI:
    10.6004/jnccn.2020.7663
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO-GU 2020
    Title:

    Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer.

    Published date:
    02/13/2020
    Excerpt:
    AR amplification and TP53 or RB1 defect were associated with resistance to abiraterone or docetaxel.
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    ASCO 2020
    Title:

    Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer.

    Published date:
    05/28/2020
    Excerpt:
    AR amplification and TP53 or RB1 defect were associated with resistance to abiraterone or docetaxel. CDK12 was more frequently altered in our cohort than those in previous reports which mainly focused on Caucasian population. The patients with CDK12 defect showed rapid resistance to abiraterone and limited efficacy of Poly (ADP-ribose) polymerase inhibitors (PARPi). However, these patients seemed to benefit from chemotherapy, especially platinum-based chemotherapy.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e17556